Reshaping Risk/Reward in Biotech VC
As returns from internet start-ups continue to reshape venture capital, the risk/reward ratios for biotech companies become less attractive for VC's. Since the biotechnology industry plays a direct role in improving health care, perhaps what's needed are investment incentives provided by public policy.
You may also be interested in...
Netherlands' Medicines Evaluation Board says the safety of paracetamol is "not up for debate" after a media investigation reported contamination of the drug with a possible human carcinogen.
There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.
In the EU, voices calling for a postponement of the IVD Regulation’s 2022 enforcement date are growing louder.